Increased Expression of ERCC2 Gene in Head and Neck Cancer is Associated with Aggressive Tumors: A Systematic Review and Case-Control Study

Zafeer, Maryam; Mahjabeen, Ishrat; Kayani, Mahmood Akhtar

doi:10.5301/jbm.5000186

Cited by 8 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic alterations of this gene have been linked to increased chemotherapy-sensitivity, especially to cisplatin [ 28 , 29 , 30 ]. Interestingly, ERCC2 has also been implicated in a recent meta-analysis in higher tumor stage and grade, and a positive correlation with Ki-67 in HNSCC, suggesting a more aggressive tumor phenotype [ 31 ]. However, the hazard ratio (HR) of ERCC2 ranged between 0.42 and 2.07 in the three respective publications ( Table S1 ) in our dataset, making a definitive interpretation difficult.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Background: Radiotherapy is a mainstay in head and neck squamous cell carcinoma (HNSCC) treatment but is mostly applied without stratification by molecular diagnostics. Development of reliable biomarkers may have the potential to improve radiotherapy (RT) efficacy and reduce toxicity. We conducted a systematic review to summarize the field of biomarkers in HNSCC treated by RT. Methods: Pubmed and EMBASE were searched independently by two researchers following pre-defined inclusion and exclusion criteria. Z curves were generated to investigate publication bias. OncoKB was used for identification of druggable targets. Results: 134 manuscripts remained for data extraction. 12% of tumors were AJCC/UICC stage I–II and 82% were stage III–IV. The most common biomarkers were proteins (39%), DNA (14%) and mRNA (9%). Limiting analysis to prospective data and statistically significant results, we found three potentially druggable targets: ERCC2, PTCH1 and EGFR. Regarding data quality, AJCC/UICC stage was missing in 32% of manuscripts. 73% of studies were retrospective and only 7% were based on prospective randomized trials. Z-curves indicated the presence of publication bias. Conclusion: An abundance of potential biomarkers in HNSCC is available but data quality is limited by retrospective collection, lack of validation and publication bias. Improved study design and reporting quality might accelerate successful development of personalized treatments in HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They found that the expression of ERCC2 was associated with the expression of Ki-67 and an aggressive cancer phenotype and concluded that ERCC2 might be used as a biomarker for improved diagnostic and prognostic value in head and neck cancer. [ 36 ]. Huang et al analyzed ERCC2 expression by immunohistochemistry in 180 colorectal cancer patients with adjuvant chemotherapy and showed that ERCC2 was not related to survival time; moreover, similar results were observed in a study by Kassem et al [ 8 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Luo

Liao

Zhu

2018

BioMed Research International

View full text Add to dashboard Cite

Except for excision repair cross-complementing 1 (ERCC1), mRNA expression of the remaining ERCC genes has not been investigated in the prognosis of gastric cancer (GC). The present study aimed to explore the mRNA expression and prognostic values of each member of the ERCC family in GC patients by using the Kaplan–Meier (KM) plotter tool. The details of each ERCC family member were entered into a database and GC patients were separated into high and low expression to draw survival plots using the KM plotter. In the present study, we observed that high expression of ERCC1 mRNA was significantly associated with longer overall survival (OS) for all GC patients (hazard ratio [HR]=0.77, 95% confidence intervals [CI]=0.63–0.95, P=0.016) compared with low expression. High expression of ERCC4 and ERCC6 mRNA indicated a worse OS for all GC patients (HR=1.28, 95% CI=1.02–1.6, P=0.035 and HR=1.25, 95% CI=1.02–1.54, P=0.029, respectively) and especially for patients with intestinal-type GC (HR=1.87, 95% CI=1.26–2.79, P=0.0018 and HR=1.62, 95% CI=1.04–2.54, P=0.033, respectively). High ERCC8 mRNA expression indicated a worse OS for all GC patients (HR=1.34, 95% CI=1.02–1.76, P=0.034) and especially for patients with diffuse-type GC (HR=2.25, 95% CI=1.36–3.75, P=0.0013). In conclusion, our findings indicate that ERCC4, ERCC6, and ERCC8 may be potential biomarkers for GC prognosis and may serve as potential therapeutic targets for GC. However, these findings still need further verification.

show abstract

“…For example, REG1 was shown to be significantly associated with survival in head and neck cancer [4]. The PD-L1 expression value was validated to have impact on many processes [5], and ERCC2 was reported to be associated with aggressive HNSCC [6]. Expression of C1GALT1 predicts the poor survival of head and neck cancer [7].…”

Section: Introductionmentioning

confidence: 99%

Fifteen mRNA-lncRNA expression-based signature predicted the survival of late-staged head and neck squamous cell carcinoma

Ren

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Abstract Background: Gene expression is necessary for regulation in almost all biological processes, at the same time, it is related to the prognosis for head and neck squamous cell carcinoma (HNSCC). The prognosis of late-staged HNSCC is important because of its guiding significance on the therapy strategies. Methods: In this work, we analyzed the relationship between gene expression and HNSCC in The Cancer Genome Atlas (TCGA) cohort, and optimized the panel with random forest survival analysis. Subsequently, a Cox multivariate regression-based model was developed to predict the clinical outcome of HNSCC. The performance of the model was assayed in the training cohort and validated in another three independent cohorts (GSE41614, E-TABM-302, E-MTAB-1328). The underlying pathways significantly associated with the model were identified. According to the results, patients of low-score group (median survival months: 27.4, 95% CI: 18.2–43) had a significant poor survival than those of high-score group (median survival months: 69.4, 95% CI: 58.7–72.1, P=2.7e-5), and the observation was repeatable in the other validation cohorts. Further analysis revealed that the model performed better than the other clinical indicators and is independent of these indicators. Results: Comparison revealed that the model performed better than existing models for late HNSCC prognosis. Gene set enrichment analysis (GSEA) elucidated that the model was significantly associated with various cell processes and pathways.

show abstract

Increased Expression of ERCC2 Gene in Head and Neck Cancer is Associated with Aggressive Tumors: A Systematic Review and Case-Control Study

Abstract: Our data suggest that deregulation of ERCC2 in HNC has the potential to predict a more aggressive cancer phenotype and may be considered a possible biomarker for improved diagnosis and prognosis of HNC.

Cited by 8 publications

References 55 publications

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review

Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Fifteen mRNA-lncRNA expression-based signature predicted the survival of late-staged head and neck squamous cell carcinoma

Contact Info

Product

Resources

About